GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celldex Therapeutics Inc (NAS:CLDX) » Definitions » Cost of Goods Sold

Celldex Therapeutics (Celldex Therapeutics) Cost of Goods Sold : $0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 1990. Start your Free Trial

What is Celldex Therapeutics Cost of Goods Sold?

Celldex Therapeutics's cost of goods sold for the three months ended in Dec. 2023 was $0.00 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Celldex Therapeutics's Gross Margin % for the three months ended in Dec. 2023 was 100%.

Cost of Goods Sold is also directly linked to Inventory Turnover.


Celldex Therapeutics Cost of Goods Sold Historical Data

The historical data trend for Celldex Therapeutics's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celldex Therapeutics Cost of Goods Sold Chart

Celldex Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cost of Goods Sold
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Celldex Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cost of Goods Sold Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Celldex Therapeutics Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Celldex Therapeutics  (NAS:CLDX) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Celldex Therapeutics's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %=(Revenue - Cost of Goods Sold) / Revenue
=(4.131 - 0) / 4.131
=100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

Celldex Therapeutics's Inventory Turnover for the three months ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.


Celldex Therapeutics Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of Celldex Therapeutics's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.


Celldex Therapeutics (Celldex Therapeutics) Business Description

Traded in Other Exchanges
Address
53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
Executives
Garry Arthur Neil director 555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Cheryl Cohen director C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Rita Jain director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Tibor Keler officer: Sen. VP & Ch Scientific Off. 30 PARK ROAD, OTTSVILLE PA 18942
Sarah Cavanaugh officer: SVP of Corp. Affairs & Admin. C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Diane C. Young officer: SVP, Chief Medical Officer 175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103
Anthony S Marucci director, officer: President and CEO 66 COLD HILL DRIVE, MENDAHM NJ 07945
Richard M. Wright officer: Sr. VP & CCO C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Samuel Bates Martin officer: SVP and CFO C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Margo Heath-chiozzi officer: SVP of of Regulatory Affairs C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Elizabeth Crowley officer: SVP, Chief Product Dev Officer C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Freddy A. Jimenez officer: SVP & General Counsel C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
James J Marino director C/O ONCONOVA THERAPEUTICS, 375 PHEASANT RUN, NEWTOWN PA 18940
Keith L Brownlie director 777 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591
Gerald Phd Mcmahon director 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114

Celldex Therapeutics (Celldex Therapeutics) Headlines